Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Colorectal Adenomas and Cancers After Childhood Cancer Treatment: A DCOG-LATER Record Linkage Study.

Teepen JC, Kok JL, van Leeuwen FE, Tissing WJE, Dolsma WV, van der Pal HJ, Loonen JJ, Bresters D, Versluys B, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, van den Berg MH, van der Heiden-van der Loo M, Hauptmann M, Jongmans MC, Overbeek LI, van de Vijver MJ, Kremer LCM, Ronckers CM; DCOG-LATER Study Group .

J Natl Cancer Inst. 2018 Jul 1;110(7):758-767. doi: 10.1093/jnci/djx266.

PMID:
29986097
2.

Downgrading of Breast Masses Suspicious for Cancer by Using Optoacoustic Breast Imaging.

Menezes GLG, Pijnappel RM, Meeuwis C, Bisschops R, Veltman J, Lavin PT, van de Vijver MJ, Mann RM.

Radiology. 2018 Aug;288(2):355-365. doi: 10.1148/radiol.2018170500. Epub 2018 Apr 17.

PMID:
29664342
3.

Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer.

Savci-Heijink CD, Halfwerk H, Koster J, Van de Vijver MJ.

BMC Cancer. 2017 Nov 13;17(1):755. doi: 10.1186/s12885-017-3691-9.

4.

Corrigendum: A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers.

Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Viari A, Easton D, Evan G, Campbell PJ, Stratton MR, Nik-Zainal S.

Nat Genet. 2017 Oct 27;49(11):1661. doi: 10.1038/ng1117-1661a.

PMID:
29074948
5.

Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.

Creemers A, Krausz S, Strijker M, van der Wel MJ, Soer EC, Reinten RJ, Besselink MG, Wilmink JW, van de Vijver MJ, van Noesel CJM, Verheij J, Meijer SL, Dijk F, Bijlsma MF, van Oijen MGH, van Laarhoven HWM.

Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):394-403. doi: 10.1016/j.bbcan.2017.08.002. Epub 2017 Aug 8. Review.

PMID:
28801248
6.

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.

Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.

Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.

7.

First-in-Human Ultrasound Molecular Imaging With a VEGFR2-Specific Ultrasound Molecular Contrast Agent (BR55) in Prostate Cancer: A Safety and Feasibility Pilot Study.

Smeenge M, Tranquart F, Mannaerts CK, de Reijke TM, van de Vijver MJ, Laguna MP, Pochon S, de la Rosette JJMCH, Wijkstra H.

Invest Radiol. 2017 Jul;52(7):419-427. doi: 10.1097/RLI.0000000000000362.

PMID:
28257340
8.

A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers.

Glodzik D, Morganella S, Davies H, Simpson PT, Li Y, Zou X, Diez-Perez J, Staaf J, Alexandrov LB, Smid M, Brinkman AB, Rye IH, Russnes H, Raine K, Purdie CA, Lakhani SR, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Viari A, Easton D, Evan G, Campbell PJ, Stratton MR, Nik-Zainal S.

Nat Genet. 2017 Mar;49(3):341-348. doi: 10.1038/ng.3771. Epub 2017 Jan 23. Erratum in: Nat Genet. 2017 Oct 27;49(11):1661.

9.

Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist.

van Rijssen LB, Rombouts SJ, Walma MS, Vogel JA, Tol JA, Molenaar IQ, van Eijck CH, Verheij J, van de Vijver MJ, Busch OR, Besselink MG; Dutch Pancreatic Cancer Group.

Surg Pathol Clin. 2016 Dec;9(4):539-545. doi: 10.1016/j.path.2016.05.002. Epub 2016 Sep 28. Review.

PMID:
27926358
10.

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.

Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW.

Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910.

11.

Low risk of recurrence in elderly patients treated with breast conserving therapy in a single institute.

van der Leij F, van Werkhoven E, Bosma S, Linn SC, Rutgers EJ, van de Vijver MJ, Bartelink H, Elkhuizen PHM, Scholten A.

Breast. 2016 Dec;30:19-25. doi: 10.1016/j.breast.2016.08.004. Epub 2016 Aug 29.

PMID:
27587341
12.

Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.

She QB, Gruvberger-Saal SK, Maurer M, Chen Y, Jumppanen M, Su T, Dendy M, Lau YK, Memeo L, Horlings HM, van de Vijver MJ, Isola J, Hibshoosh H, Rosen N, Parsons R, Saal LH.

BMC Cancer. 2016 Aug 2;16:587. doi: 10.1186/s12885-016-2609-2.

13.

Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype.

McConechy MK, Färkkilä A, Horlings HM, Talhouk A, Unkila-Kallio L, van Meurs HS, Yang W, Rozenberg N, Andersson N, Zaby K, Bryk S, Bützow R, Halfwerk JB, Hooijer GK, van de Vijver MJ, Buist MR, Kenter GG, Brucker SY, Krämer B, Staebler A, Bleeker MC, Heikinheimo M, Kommoss S, Blake Gilks C, Anttonen M, Huntsman DG.

J Natl Cancer Inst. 2016 Jun 13;108(11). pii: djw134. doi: 10.1093/jnci/djw134. Print 2016 Nov.

14.

The topography of mutational processes in breast cancer genomes.

Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S.

Nat Commun. 2016 May 2;7:11383. doi: 10.1038/ncomms11383.

15.

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, van't Veer L, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2016 Jun 2;534(7605):47-54. doi: 10.1038/nature17676. Epub 2016 May 2.

16.

CT-Colonography vs. Colonoscopy for Detection of High-Risk Sessile Serrated Polyps.

IJspeert JE, Tutein Nolthenius CJ, Kuipers EJ, van Leerdam ME, Nio CY, Thomeer MG, Biermann K, van de Vijver MJ, Dekker E, Stoker J.

Am J Gastroenterol. 2016 Apr;111(4):516-22. doi: 10.1038/ajg.2016.58. Epub 2016 Mar 29.

PMID:
27021193
17.

Very low local recurrence rates after breast-conserving therapy: analysis of 8485 patients treated over a 28-year period.

Bosma SC, van der Leij F, van Werkhoven E, Bartelink H, Wesseling J, Linn S, Rutgers EJ, van de Vijver MJ, Elkhuizen PH.

Breast Cancer Res Treat. 2016 Apr;156(2):391-400. doi: 10.1007/s10549-016-3732-0. Epub 2016 Mar 23.

PMID:
27008183
18.

A novel gene expression signature for bone metastasis in breast carcinomas.

Savci-Heijink CD, Halfwerk H, Koster J, van de Vijver MJ.

Breast Cancer Res Treat. 2016 Apr;156(2):249-59. doi: 10.1007/s10549-016-3741-z. Epub 2016 Mar 10.

19.

Computer tomography colonography participation and yield in patients under surveillance for 6-9 mm polyps in a population-based screening trial.

Tutein Nolthenius CJ, Boellaard TN, de Haan MC, Nio CY, Thomeer MG, Bipat S, Montauban van Swijndregt AD, van de Vijver MJ, Biermann K, Kuipers EJ, Dekker E, Stoker J.

Eur Radiol. 2016 Aug;26(8):2762-70. doi: 10.1007/s00330-015-4081-9. Epub 2015 Nov 11.

20.

Evolution of Screen-Detected Small (6-9 mm) Polyps After a 3-Year Surveillance Interval: Assessment of Growth With CT Colonography Compared With Histopathology.

Tutein Nolthenius CJ, Boellaard TN, de Haan MC, Nio CY, Thomeer MG, Bipat S, Montauban van Swijndregt AD, van de Vijver MJ, Biermann K, Kuipers EJ, Dekker E, Stoker J.

Am J Gastroenterol. 2015 Dec;110(12):1682-90. doi: 10.1038/ajg.2015.340. Epub 2015 Oct 20.

PMID:
26482858
21.

PTEN and NEDD4 in Human Breast Carcinoma.

Chen Y, van de Vijver MJ, Hibshoosh H, Parsons R, Saal LH.

Pathol Oncol Res. 2016 Jan;22(1):41-7. doi: 10.1007/s12253-015-9971-2. Epub 2015 Aug 15.

22.

Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Jul;152(2):253. doi: 10.1007/s10549-015-3478-0. No abstract available.

23.

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Jul;152(2):247-52. doi: 10.1007/s10549-015-3444-x. Epub 2015 Jun 4. Erratum in: Breast Cancer Res Treat. 2015 Jul;152(2):253.

24.

Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract.

Damhofer H, Ebbing EA, Steins A, Welling L, Tol JA, Krishnadath KK, van Leusden T, van de Vijver MJ, Besselink MG, Busch OR, van Berge Henegouwen MI, van Delden O, Meijer SL, Dijk F, Medema JP, van Laarhoven HW, Bijlsma MF.

J Transl Med. 2015 Apr 11;13:115. doi: 10.1186/s12967-015-0469-1.

25.

Retrospective analysis of metastatic behaviour of breast cancer subtypes.

Savci-Heijink CD, Halfwerk H, Hooijer GK, Horlings HM, Wesseling J, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Apr;150(3):547-57. doi: 10.1007/s10549-015-3352-0. Epub 2015 Mar 29.

26.

First results of the preoperative accelerated partial breast irradiation (PAPBI) trial.

van der Leij F, Bosma SC, van de Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, Bourgier C, Garbay JR, Foukakis T, Lekberg T, van den Bongard DH, van Vliet-Vroegindeweij C, Bartelink H, Rutgers EJ, Elkhuizen PH.

Radiother Oncol. 2015 Mar;114(3):322-7. doi: 10.1016/j.radonc.2015.02.002. Epub 2015 Feb 17.

27.

HLA-G expression is an independent predictor for improved survival in high grade ovarian carcinomas.

Rutten MJ, Dijk F, Savci-Heijink CD, Buist MR, Kenter GG, van de Vijver MJ, Jordanova ES.

J Immunol Res. 2014;2014:274584. doi: 10.1155/2014/274584. Epub 2014 May 27.

28.

Papillary and neuroendocrine breast lesions: the WHO stance.

Tan PH, Schnitt SJ, van de Vijver MJ, Ellis IO, Lakhani SR.

Histopathology. 2015 May;66(6):761-70. doi: 10.1111/his.12463. Epub 2015 Jan 23. Review.

PMID:
24845113
29.

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.

Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Schmidt MK, Van't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC.

Breast Cancer Res Treat. 2014 Jun;145(3):697-705. doi: 10.1007/s10549-014-2954-2. Epub 2014 Apr 24.

30.

Molecular tests as prognostic factors in breast cancer.

van de Vijver MJ.

Virchows Arch. 2014 Mar;464(3):283-91. doi: 10.1007/s00428-014-1539-0. Epub 2014 Feb 1. Review.

PMID:
24487789
31.

Long-term impact of the 70-gene signature on breast cancer outcome.

Drukker CA, van Tinteren H, Schmidt MK, Rutgers EJ, Bernards R, van de Vijver MJ, Van't Veer LJ.

Breast Cancer Res Treat. 2014 Feb;143(3):587-92. doi: 10.1007/s10549-013-2831-4. Epub 2014 Jan 21.

32.

Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.

Farazi TA, Ten Hoeve JJ, Brown M, Mihailovic A, Horlings HM, van de Vijver MJ, Tuschl T, Wessels LF.

Genome Biol. 2014 Jan 7;15(1):R9. doi: 10.1186/gb-2014-15-1-r9.

33.

Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy.

Hazewinkel Y, de Wijkerslooth TR, Stoop EM, Bossuyt PM, Biermann K, van de Vijver MJ, Fockens P, van Leerdam ME, Kuipers EJ, Dekker E.

Endoscopy. 2014 Mar;46(3):219-24. doi: 10.1055/s-0033-1358800. Epub 2013 Nov 19.

PMID:
24254386
34.

Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes.

Moelans CB, van der Groep P, Hoefnagel LDC, van de Vijver MJ, Wesseling P, Wesseling J, van der Wall E, van Diest PJ.

Cancer Lett. 2014 Mar 1;344(1):138-146. doi: 10.1016/j.canlet.2013.10.025. Epub 2013 Oct 30.

PMID:
24184827
35.

Genomic profiling of histological special types of breast cancer.

Horlings HM, Weigelt B, Anderson EM, Lambros MB, Mackay A, Natrajan R, Ng CK, Geyer FC, van de Vijver MJ, Reis-Filho JS.

Breast Cancer Res Treat. 2013 Nov;142(2):257-69. doi: 10.1007/s10549-013-2740-6. Epub 2013 Oct 27.

PMID:
24162157
36.

Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient.

Hoefnagel LD, van der Groep P, van de Vijver MJ, Boers JE, Wesseling P, Wesseling J; Dutch Distant Breast Cancer Metastases Consortium, van der Wall E, van Diest PJ.

Ann Oncol. 2013 Dec;24(12):3017-23. doi: 10.1093/annonc/mdt390. Epub 2013 Oct 10.

PMID:
24114857
37.

Routine histopathology for carcinoma in cholecystectomy specimens not evidence based: a systematic review.

Swank HA, Mulder IM, Hop WC, van de Vijver MJ, Lange JF, Bemelman WA.

Surg Endosc. 2013 Dec;27(12):4439-48. doi: 10.1007/s00464-013-3084-3. Epub 2013 Jul 23. Review.

PMID:
23877761
38.

Role of MRI in detecting involvement of the uterine internal os in uterine cervical cancer: systematic review of diagnostic test accuracy.

de Boer P, Adam JA, Buist MR, van de Vijver MJ, Rasch CR, Stoker J, Bipat S, Stalpers LJ.

Eur J Radiol. 2013 Sep;82(9):e422-8. doi: 10.1016/j.ejrad.2013.04.027. Epub 2013 May 25. Review.

PMID:
23711423
39.

Legal claims for malignant mesothelioma: dealing with all cases.

van der Bij S, Baas P, van de Vijver MJ, de Mol BA, Burgers JA.

Lung Cancer. 2013 May;80(2):153-8. doi: 10.1016/j.lungcan.2013.01.012. Epub 2013 Feb 15.

PMID:
23415607
40.

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.

Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC.

Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082. Epub 2013 Mar 4.

41.

Reliability of core needle biopsy for determining ER and HER2 status in breast cancer.

Dekker TJ, Smit VT, Hooijer GK, Van de Vijver MJ, Mesker WE, Tollenaar RA, Nortier JW, Kroep JR.

Ann Oncol. 2013 Apr;24(4):931-7. doi: 10.1093/annonc/mds599. Epub 2012 Dec 4.

PMID:
23211940
42.

Integration of clinical and gene expression data has a synergetic effect on predicting breast cancer outcome.

van Vliet MH, Horlings HM, van de Vijver MJ, Reinders MJ, Wessels LF.

PLoS One. 2012;7(7):e40358. doi: 10.1371/journal.pone.0040358. Epub 2012 Jul 11.

43.

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach.

Dekker TJ, Borg ST, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res. 2012 Jun 13;14(3):R93.

44.

Prognosis and prognostic factors of patients with mesothelioma: a population-based study.

van der Bij S, Koffijberg H, Burgers JA, Baas P, van de Vijver MJ, de Mol BA, Moons KG.

Br J Cancer. 2012 Jun 26;107(1):161-4. doi: 10.1038/bjc.2012.245. Epub 2012 May 29.

45.

Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer.

Tanis E, van de Velde CJ, Bartelink H, van de Vijver MJ, Putter H, van der Hage JA.

Eur J Cancer. 2012 Aug;48(12):1751-6. doi: 10.1016/j.ejca.2012.02.051. Epub 2012 Mar 23.

PMID:
22446021
46.

Functional characterization of the 19q12 amplicon in grade III breast cancers.

Natrajan R, Mackay A, Wilkerson PM, Lambros MB, Wetterskog D, Arnedos M, Shiu KK, Geyer FC, Langerød A, Kreike B, Reyal F, Horlings HM, van de Vijver MJ, Palacios J, Weigelt B, Reis-Filho JS.

Breast Cancer Res. 2012 Mar 20;14(2):R53.

47.

Predictive factors for local recurrence in breast cancer.

van der Leij F, Elkhuizen PH, Bartelink H, van de Vijver MJ.

Semin Radiat Oncol. 2012 Apr;22(2):100-7. doi: 10.1016/j.semradonc.2011.12.001. Review.

PMID:
22385917
48.

Search for a gene expression signature of breast cancer local recurrence in young women.

Servant N, Bollet MA, Halfwerk H, Bleakley K, Kreike B, Jacob L, Sie D, Kerkhoven RM, Hupé P, Hadhri R, Fourquet A, Bartelink H, Barillot E, Sigal-Zafrani B, van de Vijver MJ.

Clin Cancer Res. 2012 Mar 15;18(6):1704-15. doi: 10.1158/1078-0432.CCR-11-1954. Epub 2012 Jan 23.

49.

Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial.

Stoop EM, de Haan MC, de Wijkerslooth TR, Bossuyt PM, van Ballegooijen M, Nio CY, van de Vijver MJ, Biermann K, Thomeer M, van Leerdam ME, Fockens P, Stoker J, Kuipers EJ, Dekker E.

Lancet Oncol. 2012 Jan;13(1):55-64. doi: 10.1016/S1470-2045(11)70283-2. Epub 2011 Nov 15.

PMID:
22088831
50.

External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement.

Hajage D, de Rycke Y, Bollet M, Savignoni A, Caly M, Pierga JY, Horlings HM, Van de Vijver MJ, Vincent-Salomon A, Sigal-Zafrani B, Senechal C, Asselain B, Sastre X, Reyal F.

PLoS One. 2011;6(11):e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.

Supplemental Content

Loading ...
Support Center